American Academy of Dermatology Conference Coverage

AAD 2016

AAD 2016 - Citation analysisJohn Kimbrough, a librarian at Georgetown University, sits down with Dermatology Times Editorial Advisor, Elaine Siegfried, MD to talk about his work with citation analysis of cutaneous t-cell lymphoma.
AAD 2016 - Using TDABC with value-based healthcareOluwatobi A. Ogbechie, MD, MBA discusses her 2016 AAD Poster, "Measuring the costs of shave and punch biopsy techniques using time-driven activity-based costing" with Dermatology Times Editorial Advisor, Elaine Siegfried, MD.
AAD 2016 - Implementation of TeledermatologyThird-year Stanford Medical School student, Akhilesh Pathipati, discusses his 2016 AAD poster, “Implementation of Stanford Health Care Direct-Care Teledermatology Program” with Dermatology Times Editorial Advisor, Elaine Siegfried, MD.
AAD 2016 - Skin diseases associated with organochlorine exposuresAndrew T. Patterson, MD sits down with Dermatology Times Editorial Advisor, Elaine Siegfried, MD to discuss his 2016 AAD poster, “Skin diseases associated with Agent Orange and other organochlorine exposures.”
'Forgotten' systemic drugs for psoriasisWith the recent discoveries of immunologic pathways leading to psoriasis, clinicians are likely to discount older general immunosuppressive agents in favor of newer larger molecules like biologics that provide better targeted therapy.
Update on pediatric acne treatmentsDividing the pediatric population into three age groups helps streamline effective treatment for acne.
Making strides in support for psoriasis patientsThe National Psoriasis Foundation seeks support for initiatives that will provide better access for psoriasis patients to effectively treat their disease.
Sernivo: It’s all in the vehiclePromius Pharma's newly approved topical spray for psoriasis uses a sophisticated vehicle technology that allows a mid-potency steroid to act like a more potent steroid in actual clinical practice. Dr. Stein Gold explains how.
Optimizing care for patients with psoriasisIdentification of existing knowledge deficits provides insights for future research that can further improve care for patients with psoriasis.
FDA approves prescription topical Aczone for acneAllergan announced in late February that the FDA approved its topical Aczone (dapsone) Gel, 7.5% for treatment of acne vulgaris.